Chai Discovery Raises $400 Million as AI Drug Discovery Moves From Promise to Deployment

Chai Discovery Secures Major Funding Round

Chai Discovery announced it has raised $400 million in Series C funding, nearly tripling its valuation to $3.8 billion. 1

1

The round was led by Index Ventures alongside Kleiner Perkins, Sequoia Capital and Dimension, with participation from Bain Capital Ventures, Thrive Capital, OpenAI, and Yosemite, the firm founded by Reed Jobs. 1

1

This brings the AI-driven drug discovery startup's total funding to around $630 million, up from a $1.3 billion valuation in December. 2

2

The funding underscores investor interest in AI applications beyond general-purpose models, particularly in specialized fields like biotech. "I believe that life sciences is going to be one of the most consequential and biggest-impact applications of A.I.," said Nina Achadjian, a partner at Index. 1

1

How Chai Discovery Uses AI to Design Antibodies

Chai Discovery builds frontier AI models designed to accelerate AI drug discovery by predicting and reprogramming molecular interactions. 2

2

The company targets antibodies, which serve as the body's primary defense against foreign invaders. The challenge is immense: there are roughly a quintillion possible customizations that can uniquely target foreign bodies, and traditional methods involve screening millions of potential molecules one by one. 2

2

The company's latest model, Chai-3, represents a significant advancement over Chai-2, reportedly doubling success rates for molecular interactions targets to around 35% to 40% hit rates. 2

2

Instead of guessing with random molecules, Chai's AI system performs rapid simulations based on disease targets to design molecules that fit correctly, curating the vast set of possibilities to generate likely high-quality candidates. 2

2

Big Pharma Partnerships Signal Commercial Traction

Chai Discovery has secured landmark agreements with major pharmaceutical companies, demonstrating that AI-designed antibodies are reaching Big Pharma. The company signed a licensing agreement with Pfizer, granting access to Chai-3 and an AI model trained on Pfizer's proprietary data. 2

2

It has also inked a customer agreement with Eli Lilly and formed a formal collaboration with Novartis. 2

2

"Tomorrow's medicines should be designed with the precision, speed and scale of modern engineering, and this support helps us move faster towards that future," said co-founder and Chief Executive Joshua Meier. "AI drug discovery has moved from promise to deployment." 2

2

The Competitive Landscape and Industry Challenges

Chai Discovery isn't alone in attracting investor interest in AI applications for drug development. Isomorphic Labs, a spinoff from Google that draws on the technology giant's Nobel-winning work, has raised $2.7 billion from investors since March 2025. 1

1

Despite around $20 billion being poured into generative AI drug discovery, no AI-discovered drug has been approved yet. 2

2

More than 173 AI-originated drug programs are now in clinical development, up from almost two dozen in 2023, with around 15 to 20 expected to reach working trials in 2026. 2

2

The critical bottleneck appears in Phase II trials. While AI-driven discovery achieves fairly high accuracy with Phase I pass rates at 80% to 90%, success drops to around 40% in Phase II, matching traditional methods. 2

2

The life sciences industry will need to gain a better understanding of candidates and their effects as they advance into clinical trials to overcome this hurdle and deliver on the promise of AI-powered drug development.